These positive early-stage clinical results provide promising evidence supporting the continued development of XellSmart's XS411 for Parkinson's disease patients. Pioneering Achievements in ...

These milestones position XellSmart as a global leader in advancing innovative iPSC-derived regenerative cell therapies for CNS diseases, including Parkinson's disease and ALS. Dr. Michael Lee ...

Xellsmart Biopharmaceutical (Suzhou) Co. Ltd. has announced IND clearances by the FDA for its XS-411 and XS-228 cell therapies, for Parkinson’s disease and amyotrophic lateral sclerosis (ALS), ...

These positive early-stage clinical results provide promising evidence supporting the continued development of XellSmart's XS411 for Parkinson's disease patients. XellSmart has developed XS228, the ...

The in vitro modeling of human disease via iPSC-technology has proven successful for numerous developmental and early-onset disorders. However, recreating the pathogenesis of age-dependent conditions ...

This study was officially approved by China's National Health Commission, making XellSmart the first to complete an iPSC-derived cell therapy for Parkinson's disease in China. In the clinical ...

for its universal allogeneic off-the-shelf iPS-derived dopaminergic neural progenitor cell therapy for the treatment of Parkinson's disease ... clinical-grade iPSC-derived cell drug development ...

for its universal allogeneic off-the-shelf iPS-derived dopaminergic neural progenitor cell therapy for the treatment of Parkinson's disease (PD), the second most common neurodegenerative ... signifies ...